United Therapeutics Corporation
United Therapeutics develops and commercializes products for chronic and life-threatening diseases. Products include Tyvaso DPI, Tyvaso, Remodulin, Orenitram, Adcirca, Unituxin, and Remunity Pump. The company also develops RemoPro, Ralinepag, Aurora-GT, and Nebulized Tyvaso. Licensing agreements include DEKA Research, MannKind Corporation, and Arena Pharmaceuticals. The company was incorporated in 1996 and is headquartered in Maryland.
Overview
Strengths
- With an appreciation Potential of 74.69%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (11.16) is lower than the sector mean (289.29).
- Price to book ratio (2.07) is lower than the sector mean (733.70).
- The company has low debt. Net Debt to EBITDA Ratio is -0.81 and it is lower than the sector mean.
- The company has high returns. ROIC (19.68%) is higher than the sector mean (14.71%).
- EV/EBITDA (6.92) is lower than the sector mean (51.86).
- EV/EBIT (7.55) is lower than the sector mean.
- Price to free cash flow (12.34) is lower than the sector mean.
- Strong EBITDA Margin of 59.97%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data
| Indicator | Value |
|---|
| PER | 10.6 |
| EV/EBITDA | 6.5 |
| Price/Free Cash Flow' | 11.7 |
| ROIC | 19.7% |
| Net Debt/EBITDA | -0.8 |